Bellinzona, August 31, 2020 – MV BioTherapeutics is participating at this important annual event and virtually meet potential investors and licensing partners.
Please contact us for a personal meeting within the partnering system or outside it.
About MV BioTherapeutics
1. ApyraVax with the lead indication of Clostridioides difficile infection
2. ApyraMed with lead indications as immune modulator in cancer and beneficial for the gut ecosystem
Research experiments and preclinical trials are performed in the research lab hosted at IRB. The company is looking for seed funding in order to move forward as a fully operational company into clinics with the main indications.